In a fascinating look at one aspect of pharma pricing, Forbes' Matthew Herper explores the area of rebates, providing a chart of the biggest givebacks.
When Lipitor's first copycats were unleashed, Pfizer manned the battlements. As The Wall Street Journal reports, that battle is over.
Just how important resolving manufacturing problems can be to a drugmaker's upside was evident in the skyrocketing first-quarter earnings of Ranbaxy Laboratories.
Ranbaxy Laboratories' first-quarter earnings soared on its launch of the cholesterol drug copycat.
Pfizer's mission to expand Lyrica use just hit a couple of roadblocks.
Followers of Pfizer won't be surprised to learn of Read's M&A appetite, yet the pharma chief happens to be scouting for deals at an interesting time in the industry and at his company.
The Chicago-based company petitioned the FDA to stop biosimilar versions of Humira, its lead drug, on trade-secret grounds.
The pharma giant is staying focused on the fate of a trio of late-stage therapies that are desperately needed to fill a growing gap.
Lipitor sales tanked 42%, and though sales of other products grew, overall pharma sales dropped 25%.
Getting FDA approval of a new plant in India meant Ranbaxy was able to push out enough generic Lipitor in March to take the top spot in production of the drug.